Relay Therapeutics (RLAY) Set to Post Earnings on Thursday

Relay Therapeutics (NASDAQ:RLAY) is expected to announce its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect the company to announce earnings of ($0.3964) per share and revenue of $1.62 million for the quarter. Parties are encouraged to explore the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Wednesday, November 4, 2026 at 4:00 PM ET.

Relay Therapeutics (NASDAQ:RLAY) last released its earnings results on Thursday, August 6th. The company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.02). The company had revenue of $0.35 million during the quarter, compared to analysts’ expectations of $0.96 million. On average, analysts expect Relay Therapeutics to post ($1.61) EPS for the current fiscal year and ($1.62) EPS for the next fiscal year.

Relay Therapeutics Trading Up 4.5%

NASDAQ RLAY opened at $19.69 on Thursday. The business’s 50-day moving average price is $18.57 and its 200 day moving average price is $14.84. Relay Therapeutics has a twelve month low of $5.95 and a twelve month high of $21.27. The company has a market capitalization of $4.31 billion, a PE ratio of -12.54 and a beta of 1.72.

Insiders Place Their Bets

In related news, major shareholder Pauling (Cayman) Ltd Svf sold 6,000,000 shares of the stock in a transaction that occurred on Tuesday, August 25th. The shares were sold at an average price of $19.40, for a total transaction of $116,400,000.00. Following the completion of the sale, the insider owned 21,904,963 shares of the company’s stock, valued at approximately $424,956,282.20. This represents a 21.50% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Peter Rahmer sold 4,508 shares of the stock in a transaction that occurred on Wednesday, August 26th. The stock was sold at an average price of $20.03, for a total transaction of $90,295.24. Following the sale, the insider directly owned 223,657 shares of the company’s stock, valued at approximately $4,479,849.71. This trade represents a 1.98% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 6,144,870 shares of company stock worth $119,102,319. 5.04% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several analysts have commented on the company. Canaccord Genuity Group initiated coverage on shares of Relay Therapeutics in a research note on Thursday, July 16th. They set a “buy” rating and a $29.00 price objective for the company. Citigroup reiterated a “market outperform” rating on shares of Relay Therapeutics in a report on Monday, August 10th. Zacks Research raised shares of Relay Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Thursday, August 20th. The Goldman Sachs Group boosted their target price on shares of Relay Therapeutics from $22.00 to $31.00 and gave the company a “buy” rating in a report on Tuesday, July 21st. Finally, JPMorgan Chase & Co. boosted their target price on shares of Relay Therapeutics from $28.00 to $31.00 and gave the company an “overweight” rating in a report on Friday, August 14th. Two research analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $25.92.

Relay Therapeutics Company Profile

Relay Therapeutics, Inc is a biotechnology company focused on discovering and developing medicines for cancer and other serious diseases. The company uses its Dynamo platform, which combines structural biology, computational modeling, machine learning and experimental science to study how proteins move and interact. Relay aims to use this approach to identify precisely targeted therapies, including medicines designed to bind to previously difficult-to-drug sites.

The company’s pipeline has primarily focused on oncology, including investigational small-molecule therapies directed at cancer-driving proteins and signaling pathways.